Click "Register" to access Recording.
Just over 10 years ago, the first agent for HIV pre-exposure prophylaxis was approved in the United States. Since then, the landscape of PrEP has shifted, with approval of additional PrEP medications and growth of low-threshold PrEP delivery strategies, such as same-day PrEP. In this interactive webinar, Dr. Kevin Ard discussed new medications in the pipeline for PrEP and emerging PrEP delivery models.
This session offers 1.0 credit of CME.
Check out the topic page, Pre-Exposure Prophylaxis (PrEP), from NEAETC's online HIV Resource Library.
